天境生物科技（上海）有限公司 IMab
{{company.company_channel.channel_name}}
Media Room
{{company.company_name_local}}
{{company.company_channel.channel_name}}
Company Profile
Media Room
I-Mab Provides Business and Corporate Updates and Reports Financial Results for the Year Ended December 31, 2022 2023-03-31 18:30
I-Mab to Report Full Year 2022 Financial Results and Provide Corporate Update on March 31, 2023 2023-03-20 20:00
MSCI ESG Updated I-Mab to "A" Rating 2023-03-07 21:02
I-Mab Announces Two Poster Presentations of CD47 Antibody Lemzoparlimab at ASH 2022 2022-11-03 21:01
I-Mab Announces Approval from China CDE to Initiate Phase 3 Registrational Study of Lemzoparlimab in Combination with Azacitidine in Higher-Risk Myelodysplastic Syndrome 2022-09-13 20:00
I-Mab Announces Positive Phase 2 Data of Lemzoparlimab in Combination with Azacitidine (AZA) in Patients with Higher Risk Myelodysplastic Syndrome at ESMO 2022 2022-09-10 21:00
I-Mab Provides Business and Corporate Updates and Reports Financial Results for the Six Months Ended June 30, 2022 2022-08-30 18:00
I-Mab Announces Share Purchase Plans by the Company and the Senior Management 2022-08-23 21:13
I-Mab to Report Business and Corporate Updates and Financial Results for the Six Months Ended June 30, 2022 on August 30, 2022 2022-08-19 21:00
I-Mab to Present Phase 2 Clinical Data of CD47 Antibody Lemzoparlimab at ESMO Congress 2022 2022-07-18 20:00
I-Mab to Host 2022 R&D Day 2022-07-06 20:00
I-Mab Receives Top Rankings in Five Categories by Institutional Investor 2022-06-23 20:00
I-Mab Partner MorphoSys Announces New License Agreements for Felzartamab and TJ210 2022-06-15 22:37
I-Mab Announces Completion of Patient Enrollment in Phase III Clinical Trial of Eftansomatropin alfa for Treatment of Pediatric Growth Hormone Deficiency 2022-05-31 20:00
I-Mab Reports Latest Phase 2 Clinical Data of its Differentiated CD73 Antibody Uliledlimab 2022-05-27 05:01
I-Mab to Hold Investor Call to Report Latest Phase 2 Clinical Data of its Differentiated CD73 Antibody Uliledlimab 2022-05-19 20:00
I-Mab Provides Updates on Status under Holding Foreign Companies Accountable Act 2022-05-05 20:00
I-Mab Announces Appointments of Richard Yeh as Chief Operating Officer and John Hayslip as Chief Medical Officer 2022-04-29 04:01
I-Mab Announces Voluntary Lock-ups by Key Shareholders and Senior Management for Long-Term Commitment 2022-03-31 20:00
I-Mab Provides Business and Corporate Updates and Reports Financial Results for the Year Ended December 31, 2021 2022-03-29 18:10
1 2 3 4 5 8